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ABSTRACT Lung surfactant protein, SP-B, and synthetic amphipathic peptides derived from SP-B were studied in model lung surfactant
lipid bilayers by immunofluorescent labeling. Liposomes were formed by hydrating a lipid film on the glass viewing port of a temperature
controlled flow chamber. Membrane associated peptides were detected by epifluorescence optical microscopy of the binding of
anti-peptide polyclonal monospecific antibodies and FITC-conjugated secondary antibodies added to buffer contained in the flow
chamber. Liposomes were bound by antibody to residues 1-25 of SP-B if formed from lipid films containing the 1-25 peptide, (SP-B(1 -
25)), or if SP-B(1 -25) was added to already formed liposomes in buffer solution. The distribution of antigen-antibody complex was
temperature dependent with aggregation occurring at .300C. Surface association was not detected in liposomes formed from lipid films
containing the 49-66 peptide (SP-B(49-66)), using an antibody to the 49-66 peptide, or to a synthetic version of the SP-B protein,
(SP-B(1 -78)), using both antibodies to the 49-66 peptide and the 1-25 peptide. The detection of SP-B(1 -78) with antibody to the 49-66
sequence was only possible after reducing SP-B(1 -78) with dithiothreitol, suggesting that the COOH-terminus of the full monomer protein
is accessible to the bulk aqueous environment unlike the COOH-terminal peptide. The size, number of layers, and fluidity of the
liposomes were not altered by protein or peptides, although they were affected by lipid composition and temperature.
INTRODUCTION
A mixture of lipids and proteins, commonly known as
lung surfactant, lines the airspaces of the lungs of all
mammalian species. This mixture stabilizes the lung al-
veoli during breathing by varying the air-surfactant in-
terfacial tension according to alveolar curvature, ensur-
ing that alveoli neither collapse nor rupture. The interfa-
cial tension is changed by rapid adsorption, desorption,
and compression ofsurfactant at the air-surfactant inter-
face during each breathing cycle (1-3). Lung surfactant
contains at least four specific proteins: SP-A, SP-B, SP-
C, and SP-D (4, 5), along with several lipid species,
primarily dipalmitoylphosphatidylcholine, phosphati-
dylglycerol, phosphatidylinositol, and phosphatidyletha-
nolamine. SP-B and SP-C are low molecular weight hy-
drophobic proteins with reduced molecular weights of 5
and 3.5 kD, respectively, that appear to be important to
surfactant function in vivo (6). These proteins co-isolate
with lipid extract of surfactant prepared by chloroform-
methanol extraction, and enhance adsorption of surfac-
tant lipids to an air-water interface in vitro (7-10). Pre-
mature infants with insufficient amounts of lung surfac-
tant suffering from Respiratory Distress Syndrome
(RDS) have been successfully treated with exogenous
surfactants that contain SP-B and SP-C extracted from
animal or human sources (8, 11-13). Other surfactant
therapies mix bovine or porcine SP-B and SP-C with
synthetic lipids or extracted lung lipids (6, 14-17), also
with reasonable success. However, the detailed role of
SP-B or SP-C in enhancing surfactant function is still not
well understood.
The association with surfactant molecules and struc-
ture in lipids of SP-B and its amphipathic peptides have
been studied using several model lipid mixtures and by
various physical measurements. We have focused on the
study of two amphipathic peptides of SP-B based on
published sequence data for human SP-B (18-21). These
synthesized domains include the NH2-terminal residues
1-25, which are known as SP-B(I-25), and the COOH-
terminal residues 49-66, which are called SP-B(49-66).
Compared with lipid alone, mixtures of SP-B(1-25) and
SP-B(49-66) in lipid had lower minimum surface ten-
sions and higher rates of surface adsorption (22, 23). SP-
B(I-25) has a high affinity for negatively charged lipid
monolayers and readily inserts into negatively charged
lipid monolayers (22). The surface activity of SP-B(1-
25), SP-B(49-66), and synthetic whole SP-B(1-78) has
been correlated with their secondary structures in mem-
brane mimicking and synthetic surfactant lipid environ-
ments. Circular Dichroism (CD) and Fourier Transform
Infra-Red (FTIR) Spectroscopy of surfactant lipid-pep-
tide multilayer films indicate that the SP-B peptides as-
sume largely helical conformations in membrane envi-
ronments (22, 24, 25). The association of enhanced sur-
face activity and high helical secondary structure for
these peptides in membrane mimic environments is con-
sistent with the observation that these peptides consist of
elements predicted to be amphipathic by the alpha hy-
drophobic moment analysis (26) ofthe SP-B amino acid
sequence (23, 27). The coordinates for the SP-B se-
quences locate the SP-B amphipathic segments in the
surface sector ofthe hydrophobic moment plot near lytic
peptides such as Magainin and Melittin, suggesting that
the polar component ofthe amphipathic sequences may
have hydrophilic surface accessibility in surfactant lipid
dispersions and detergent micelles.
Immunostaining experiments have been used to de-
tect SP-B by anti-peptide antibodies to determine sur-
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face accessibility to antibody and conformational (disul-
fide linkage) differences between amphipathic peptides
and native protein (24). A continuous region of the
whole protein is surface accessible if an antibody di-
rected at a synthetic peptide of the region successfully
binds the protein (28). Binding does not occur if the di-
rected region is buried in the hydrophobic core of the
protein due to the protein configuration (29). As ex-
pected, antibodies directed against specific peptides
identified those peptides. However, antibody directed
against SP-B(1-25) identified monomeric native SP-B
(MW = 8 kD) but did not identify oligomeric native
SP-B (MW = 17 and 26 kD). This suggests that the 1-25
region of native monomeric SP-B is surface-accessible
and closely approximates the configuration of SP-B(1-
25) peptide. Antibody directed against SP-B(49-66)
identifies both oligomeric and monomeric forms of na-
tive SP-B, suggesting that this domain is readily accessi-
ble in both the oxidized and reduced form (24). How-
ever, preliminary results showed that antibody directed
against SP-B(1-25) did not bind synthetic monomeric or
oligomeric SP-B(1-78). Antibody directed against SP-
B(49-66) did not bind to synthetic oligomeric SP-B(1-
78), but did bind to monomeric SP-B(1-78). Hence, the
conformation of the synthetic protein is likely to be dif-
ferent than the native protein, especially in the NH2-ter-
minus region or 1-25 region.
Immunostaining techniques, however, fail to provide
information on the location of these low molecular
weight proteins in membranes and their ability to sponta-
neously associate with bilayers. It is also difficult to pre-
dict, using only data from immunostaining experiments,
if the 1-25 or 49-66 sequences of SP-B(1-78) or the syn-
thetic peptides are accessible to antibody in a lipid envi-
ronment. In immunostaining, protein to be identified by
antibody is adsorbed to a hydrophobic blotting mem-
brane with an aqueous solvent (30) and may be asso-
ciated with residual sodium dodecyl sulfate from electro-
phoresis. To better assess the accessibility of the protein
in its native lipid environment, it is necessary to examine
antibody binding in a more realistic model lipid mem-
brane system. In our technique, which we call flow im-
munofluorescence, giant vesicles are formed by slow
swelling ofa dried lipid film with buffer in a temperature
controlled flow chamber. The giant vesicles within the
micro-flow chamber are easily viewed in the optical mi-
croscope without additional preparation or extraction.
Peptides and proteins are detected in the vesicle bilayer
by the attachment of polyclonal monospecific antibod-
ies. FITC (fluorescein isothiocyanate)-conjugated sec-
ondary antibodies are then used to visualize the associa-
tion in the epifluorescence microscope. Similar assays
have been used to determine the molecular topography
ofproteins associated with reconstituted cell membranes
(31-33).
In addition to studies of proteins and peptides within
bilayers, flow immunofluorescence is also quite useful to
TABLE 1 Amino acid sequences of synthetic SP-B peptides











* Residues are numbered from the NH2-terminus.
N I is the nonoxidizable methionine analogue, norleucine.
§ CONH2 represents carboxyamidation of the COOH-terminus.
determine membrane binding characteristics of water
soluble proteins. Since SP-B(1-25) is water soluble, this
system is well suited for the injection of SP-B( 1-25) into
preformed vesicle solutions of various composition to
detect peptide insertion into lipid bilayers. Of particular
interest is the affinity of SP-B(1-25) (which is positively
charged at neutral pH as it contains two lysine and two
arginine residues) to neutral dipalmitoylphosphatidyl-
choline (DPPC) vesicles, DPPC/egg phosphatidylglyc-
erol (PG) vesicles, and DPPC/palmitic acid vesicles. We
can also observe vesicles of different lipid compositions
through the flow chamber to examine composition de-
pendent shape changes and peptide-antibody complex
redistribution with temperature or composition. We
make general correlations between vesicle shape, effec-
tiveness, and composition using this simple visualization
technique. In this fashion, we have determined a signifi-




L-Ca Dipalmitoylphosphatidylcholine, egg phosphatidylglycerol, and
palmitic acid were purchased from Sigma Chemical Co. (St. Louis,
MO) and were used without further purification. Dithiothreitol was
purchased from Pierce Chemical Co. (Rockford, IL). Fluorescein iso-
thiocyanate (FITC)-conjugated goat anti-rabbit (GAR) antibody was
obtained from Orgenon Technica (Durham, NC).
Peptide synthesis
Synthetic peptides representing the NH2-terminal amino acid sequence
(residues 1-25), the COOH-terminus (residues 49-66), and full length
SP-B (residues 1-78) (Table 1) were synthesized at the UCLA Peptide
Synthesis Facility. The SP-B(1-25) segment and the SP-B(49-66) seg-
ment were synthesized using the Merrifield method employing a BOC
strategy (23, 34). Full length SP-B( 1-78) was synthesized also using the
solid phase method with BOC protected amino acids (25). The crude
peptides were purified by C4 (Vydac, C4) reverse phase HPLC using a
water-acetonitrile gradient containing 0.1% trifluoroacetic acid. HPLC
solvents and ion pairing agents were removed from the purified pep-
tides by vacuum centrifugation. The expected molecular mass for SP-
B(1-25) and SP-B(49-66) was obtained by FAB-Mass Spectrometry










FIGURE 1 Temperature controlled micro-flow chamber used in immu-
nofluorescence experiments. The chamber is made by sandwiching a
teflon spacer [1], an o-ring [2], and two glass cover slips [3, 4] between
two black anodized plates [5, 6]. Liposomes formed in the solution
volume between the two cover slips remain attached to the bottom
cover slip as buffer solutions are exchanged through inlet and outlet
capillaries [7, 8]. The solution volume is temperature controlled by an
attached thermofoil heater [10] and resistive temperature probe [11].
(A and B) Cross-sectional views of flow chamber (scales in X and Y
direction are different).
(City of Hope Mass Spectrometry Facility, Duarte, CA). The amino
acid sequence for synthetic SP-B( 1-78) was confirmed by sequencing
the peptide from residue 1 to 78 with an ABI 470A protein sequencer
(25) and the expected molecular mass was obtained by electrospray
mass spectroscopy (NPI Analytical Chemistry Facility).
Antibodies to synthetic peptides
For preparation of anti-SP-B( 1-25) and SP-B(49-66) antibodies, New
Zealand White rabbits were injected with 200 Mg of peptide, in the
presence of Freund's adjuvant (24). After 3 wk, the rabbits were given a
booster injection with 500 Mg of incomplete Freund's adjuvant. The
animals were bled 11 d after the last immunization. Synthetic peptides
were injected into rabbits in Freund's adjuvant without conjugation so
as not to alter the antigenic properties of the peptide moiety (35).
Temperature controlled flow chamber
The flow immunofluorescence chamber (Fig. 1) is constructed by sand-
wiching a Teflon spacer [1], an o-ring [2], and two glass cover slips [3,
4] between two black anodized aluminum plates [5, 6]. The top and
bottom plates have a through hole at their centers, 1.5 cm and 2 cm in
diameter, respectively, as a viewing port and to allow the objective lens
to seat close to the glass cover slip. The Teflon spacer has two closely
spaced inlet and outlet capillaries [7, 8] (26 gauge stainless steel needle
bores) used for exchange of rinse buffers and buffer containing peptide
or antibodies. The whole assembly is held together by four screws
through the aluminum plates [9]. The exchange volume is small (0.3
ml), which allows for the use ofvery little antibody solution. Tempera-
ture regulation from 20 to 50°C is achieved by an attached thermofoil
heater (HK 5542 R25.5) [10] and resistive temperature probe [11]
(S651; Minco, Minneapolis, MN) controlled by a microprocessor-
based temperature controller (CN 9000; Omega, Stamford, CT). The
heater is placed in a depression on the aluminum plates so as to mini-
mize the amount of aluminum heated. The temperature probe is held
with adhesive to the glass on the opposite side of the heater. The time
required to heat the buffer contained in the chamber from room tem-
perature to 43°C is ~-5 min. Temperature control of±0.1 °C was easily
achieved after properly tuning the controller. The temperature gradient
across the water-filled sample chamber, while the chamber was held at
43°C, was measured by affixing an additional resistive temperature
probe to the glass on the heater side and measuring the resistivity of
both temperature probes. The temperature difference between the top
and bottom cover glass was <1 °C. This chamber is similar in concept
to a measuring chamber used to visualize the incorporation of K- 1
antigen into giant liposomes (36). The main difference is that the tem-
perature control ofthe chamber described here is much more compact;
temperature control is obtained by an easily portable controller and
heater rather than a water bath. Our design also has the advantage that
the Teflon spacers can easily be made of different thicknesses and the
sample touches only glass, Teflon, and the stainless steel needle bores.
Buffer solutions were injected into the chamber slowly (0.5 ml/min)
through (0.025 in ID) HPLC tubing (Becton Dickinson and Company,
(Parsippany, NJ) with a syringe pump (341B; Orion, Boston, MA).
Formation of giant liposomes
In a typical experiment, 2.55 mg DPPC, 0.79 mg egg PG, 0.30 mg
palmitic acid (this ratio of DPPC:PG:PA is called Tanaka lipids (9)),
and 0.1 1 mg SP-B peptide were dissolved in 0.5 ml ofchloroform:meth-
anol (2:1 vol:vol) solution. Small drops (<0.5 ul) of the chloroform/
methanol solution containing the desired lipid mixture were then de-
posited on a cover slip and the solvent removed by a stream of dry
nitrogen gas followed by several hours under moderate vacuum. The
cover slip was then placed into the flow immunofluorescence chamber
which was then assembled and filled with room temperature 10 mM
phosphate buffered normal saline (PBS), with 0.5% bovine serum albu-
min (BSA) at pH 7.2. The chamber temperature was raised to 43°C
(above the 41 °C gel-liquid crystal transition temperature of DPPC
(37)) and the lipid was allowed to swell for I h during which time giant
vesicles formed. Below this temperature, giant vesicles were slow to
form. The heater was then turned off so that the chamber returned to
room temperature. The vesicles formed in this fashion generally did
not detach from the glass cover slip during exchange of solution at
room temperature, perhaps because predominantly DPPC bilayers are
relatively rigid below the gel-fluid phase transition of the lipid. The
formation of mainly uni- or multi-lamellar vesicles depended upon the
composition of the lipid film deposited.
Microscopy
Microscopic observations were performed using an Olympus IMT-2
Inverted Research Microscope with a 40X lens (Olympus long working
distance, CD Plan 40 PL, numerical aperture 0.6). The microscope
could be operated in either epifluorescence or differential interference
contrast (Nomarsky) modes. Images were recorded with an Olympus
OM-2, 35 mm camera using TMAX 400 ASA and Ektachrome 800/
1600 ASA films (Kodak, Rochester, NY). Kodak Polycontrast III RC
paper was used for prints.
RESULTS AND DISCUSSION
Surface association of SP-B(1-25)
in giant liposomes
Giant vesicles were hydrated from Tanaka lipids and SP-
B( 1-25) as discussed above, then polyclonal rabbit anti-
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FIGURE 2 (A) Epifluorescence image of labelling (large arrows) corresponding to binding of antibody (FITC-conjugated goat anti-rabbit [GAR]
antibody and polyclonal rabbit [PR] anti-SP-B [ 1-25 antibody]) to Tanaka lipid bilayer associated SP-B( 1-25). (B) Differential Interference Contrast
(DIC) image ofgiant vesicles. Large arrows indicate lipid bilayer of vesicle corresponding to A. The small arrows mark an encapsulated vesicle that
has no fluorescence associated with it because the secondary antibody can not penetrate the lipid bilayer.
SP-B( 1-25) antibody (50 ,ug in 400 ,u buffer) was injected
into the flow chamber. The antibody was incubated with
the vesicles containing peptide for 45 min at room tem-
perature. The volume ofthe flow chamber was then thor-
oughly exchanged at room temperature with 5 ml buffer
Longo et al.
(- 15 times the chamber volume), and FITC-conjugated
GAR antibody (50 jig in 400 ,ul buffer) was injected into
the chamber. After incubation at room temperature for
45 min, the chamber volume was exchanged again with
5 ml of buffer at room temperature to minimize back-
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TABLE 2 Summary of immunoreactivWies between lipid




Antigen Lipid terminus COOH-terminus
SP-B(1-25) DPPC/egg PG/PA* yes
SP-B(1-25) DPPC/egg PG yes
SP-B(1-25) DPPC/PA yes
SP-B(1-25) DPPC yes (weak)
SP-B(49-66) DPPC/egg PG/PA no
SP-B( 1-78) DPPC/egg PG/PA no no
SP-B( 1-78)
reduced DPPC/egg PG/PA no yes (diffuse, weak)
* Palmitic acid has been abbreviated as PA.
ground fluorescence. The liposomes were then exam-
ined by both differential interference contrast micros-
copy (DIC) and fluorescence microscopy to detect anti-
gen binding.
Fig. 2 shows a typical result. The fluorescence (A)
corresponds to binding ofantibody to surface associated
SP-B(I-25) and is seen as a homogeneous bright ring
(large arrows) on a dark background. Comparison ofthis
image to the DIC image (B) shows that the fluorescence
is associated with the external membrane of the giant
liposomes (large arrows). Vesicles encapsulated inside of
giant vesicles can clearly be seen in the DIC image (B)
(small arrows), but fluorescently labelled antibody is not
associated with these interior vesicles (A), indicating that
the antibody is isolated to the surface and can not pene-
trate the bilayer. The results of all experiments are sum-
marized in Table 2. If the temperature was raised to
- 30°C post-labelling, the fluorescence becomes patchy
(Fig. 3, arrows). Vesicles made from Tanaka lipids with-
out added SP-B(1-25) showed no fluorescence, confirm-
ing that the labelling was not due to nonspecific binding.
Insertion of SP-B(1-25)
into giant liposomes
Previous CD and FTIR results (22) have shown that SP-
B( 1-25) preferentially forms an a-helical structure when
in the presence of lipids or structure-forming solvent
(50% trifluoroethanol, 50% water). Examination of
amino acid positions 9 through 26 using a Shiffer-Ed-
mondson analysis (Fig. 4 A) showed segregation ofpolar
residues from nonpolar ones in two distinct hemifaces,
as is typical ofamphipathic sequences (38). We hypothe-
sized that due to this amphipathic nature, SP-B(1-25)
added to the chamber solution after vesicle formation
would spontaneously associate with the lipid membrane.
Therefore, the experimental procedure was modified so
that 50 ,g of SP-B(1-25) in 400 ,l ofbuffer was added to
giant vesicles formed of only Tanaka lipids. After incu-
bation for 45 min at 430C, the excess peptide was rinsed
from the chamber and the vesicles were labelled as de-
scribed above.
Similarly, vesicles formed from DPPC:egg PG,
2.55:0.79, DPPC:palmitic acid, 2.55:0.30, and pure
DPPC (100%) were incubated with 50 ,g of SP-B(1-25)
in 400 ,l of buffer and then labelled. In vesicles formed
of Tanaka lipids, DPPC/egg PG and DPPC/palmitic
acid, fluorescence was associated with the membranes of
these vesicles, indicating that the peptide SP-B( 1-25) did
spontaneously associate with the vesicle membranes.
The fluorescence was often slightly inhomogeneous, es-
pecially in comparison with the fluorescence observed in
the original preparation in which the peptide was mixed
with the lipids before hydration. The inhomogeneity ap-
peared to increase with increasing temperature. Marked
inhomogeneities occurred at temperatures above 30°C
for all mixtures except vesicles formed solely of DPPC.
This patching is similar to a time-dependent inhomo-
geneous distribution oflabel seen by Decher (36), which
was reported to be due to the use ofa different K- 1 anti-
gen. However, in that experiment, the observation was
done at a temperature (35°C) well above the gel-liquid
phase transition ofthe lipid used (dimyristoylphosphati-
dylcholine) (36). Hence, it is likely that the inhomogen-
eities are caused by some attractive interaction between
either the primary or secondary antibody, or the entire
complex, which can lead to aggregation much more
quickly in fluid membranes than in gel membranes.
The fluorescence associated with vesicles formed of
DPPC alone (Fig. 5) was much weaker than in vesicles
formed from the Tanaka mixture, DPPC/egg PG (Fig. 6)
or DPPC/palmitic acid vesicles and appeared to be ofan
intensity slightly above background. Note that vesicle
tubules were also labelled in the DPPC/egg PG mixture
(Fig. 6). Increasing the amount of SP-B(1-25) added to
DPPC vesicles to 100 Mg increased the membrane asso-
ciated fluorescence to a level similar to that ofthe mixed
lipid vesicles. Upon increasing the temperature, the fluo-
rescence associated with the DPPC vesicles became
patchy near the gel-liquid crystal transition of DPPC
(-41°C), again suggesting that the inhomogeneities in
labelling were due to enhanced lateral diffusion of the
antibody complex in the fluid lipids.
The weak fluorescence associated with vesicles formed
of DPPC indicates that much less peptide is bound to
uncharged DPPC vesicles than to vesicles containing
charged lipids. This observation suggests that an electro-
static interaction is necessary for initial binding of pep-
tide to vesicles. A possible explanation for the peptide-
charged lipid interaction involves a strong electrostatic
attraction between positive residues (2 lysine, 2 arginine)
and the negatively charged lipids enhancing the adsorp-
tion of SP-B(1-25). Subsequently, when the peptide ad-
sorbs to the lipid surface, it must orient and fold in such a
way that the positive residues do not interact with the
hydrophobic lipid core. The SP-B(1-25) amphipathic al-
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FIGURE 3 Temperature dependent patching of FITC-conjugated GAR antibody on giant liposomes of Tanaka lipids containing SP-B(l-25) and
PR anti-SP-B(1-25) (30°C): (A) epifluorescence image, arrows mark examples of patching, (B) DIC image.
pha helix can be oriented in the lipid bilayer so that the Association of SP-B(49-66)
hydrophobic region is in contact with the hydrophobic with giant vesicles
lipid core and the charged region is interacting with polar
headgroups and water. In this way, SP-B( 1-25) initially Vesicles formed from Tanaka lipids and 3% SP-B(49-66)
interacts electrostatically with charged lipid bilayers and mixed in chloroform/methanol, dried on cover slips
then orients in the bilayer so that its charged residues are then hydrated, were not labelled by antibody to SP-B(49-
exposed to the hydrophilic environment and may be 66). As SP-B(49-66) contains more hydrophobic resi-
bound by antibody. dues than SP-B( 1-25) and is water insoluble, our results
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FIGURE 4 Edmundson helical wheel diagrams for (A) SP-B NH2-termi-
nal residues Trp-9 (position 1) to Ala-26 (position 18); (B) SP-B
COOH-terminal residues Leu-49 (position 1) to Leu-66 (position 18).
Symbols above residues indicate charge.
suggest that this peptide is more deeply embedded in the
lipid bilayer. Due to its lack of water solubility, and its
high affinity for lipids and nonpolar solvents, we are sure
that the peptide is located within the vesicle bilayers,
although it is not in contact with the lipid-water inter-
face. Like the 1-25 region, the 49-66 region has a domi-
nant alpha helical structure in a membrane mimic envi-
ronment (24). Shiffer-Edmonson analysis of amino acid
residues 49 through 66 is shown in Fig. 4 B. However, as
there are two positively charged (arginine) and two nega-
tively charged residues (aspartine and glutamine), the
peptide has no net charge. Hence, the entire helix can be
more deeply embedded in the lipid bilayer and it will be
less accessible to antibody.
Accessibility of SP-B(1 -78) to antibody
In order to test the surface accessibility of full length
SP-B(1-78) protein domains in surfactant liposomes, li-
posomes were formed ofTanaka lipids and 3% ofthe 78
residue synthetic peptide. The liposomes were hydrated
under reducing conditions with 5 mM dithiothreitol,
such that the synthetic SP-B was noncovalently linked
by disulfide bonds. Antibodies were then added as de-
scribed above. Vesicles containing reduced SP-B(1-78)
were not bound by 1-25 antibody. Diffuse fluorescence
was associated with each vesicle labelled with antibody
to SP-B(49-66) (Fig. 7; arrows), indicating that reduced
SP-B( 1-78) incorporated in vesicles is accessible to 49-66
antibody. This type of diffuse labelling was not observed
in any other experiments. Note that the vesicles did not
protrude from the lipid film under these reducing condi-
tions. The next two experiments were identical to the
first two except that dithiothreitol was absent in the
buffer so that SP-B( 1-78) was in its oxidized form. Vesi-
cles containing oxidized SP-B(1-78) were not bound by
1-25 or 49-66 antibody.
Binding of the antibody against the NH2-terminus
does not occur with either reduced or oxidized synthetic
SP-B(1-78) in immunostaining experiments either, sug-
gesting that the lack of binding is more likely due to a
difference in protein conformation rather than a varia-
tion in accessibility. On the other hand, the antibody to
the COOH-terminus binds the full length SP-B(1-78) in
immunostaining experiments, and binds weakly in a li-
posome environment. The 49-66 peptide, however, is
not bound by antibody in a liposome environment. This
suggests that the COOH-terminus region of the full
monomeric synthetic SP-B(l-78) is more accessible to
the bulk aqueous environment than the 49-66 peptide.
Albumin is a known inhibitor oflung surfactant (39, 40).
Therefore, to eliminate the possibility that albumin was
somehow effecting the binding of antibody to SP-B,
these experiments were repeated with no BSA in the
buffer solution and the same results were obtained.
Relationship of vesicle shape
to composition
Amphiphiles can form a variety of structures; for exam-
ple, double chained surfactant molecules can assemble
to form small spherical micelles, vesicles, tubules, or bi-
layers that can transform from one structure to another
as temperature, counterions, and concentrations are var-
ied (41-43). It is not surprising that hydrated mixtures of
DPPC, DPPC/egg PG, DPPC/palmitic acid, and Tanaka
lipids formed quite different structures at 25°C which
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FHGURE 5 Weak binding of antibody (FITC-conjugated GAR antibody and PR anti-SP-B[l-25]) to SP-B(l-25) which had adsorbed to preformed
DPPC vesicles: (A) epifluorescence, (B) DIC. Comparison of this image to Fig. 6 demonstrates that SP-B( 1-25) adsorbs more readily to negatively
charged lipid bilayers than neutral DPPC bilayers.
could easily be viewed in the microscope. DPPC formed
multilayered structures ranging from -- 4 to 30 ,um (Fig.
8 A; arrow). DPPC/palmitic acid formed smaller (2 to 20
Mim) and less densely packed structures that appeared to
lie near the plane of the lipid film (Fig. 8 B; arrow).
DPPC/egg PG and DPPC/egg PG/palmitic acid packed
into spherical liposomes (Fig. 8, Cand D). DPPC/egg PG
liposomes appeared to constitute a bimodal population
(vesicle size ranges from 4 to 30 ,m); in one population,
each liposome encapsulated many tightly packed vesi-
cles that often extended close the center of the liposome
(Fig. 8 C; large arrow) and the other population mainly
consisted of vesicles that are unilamellar or encapsulated
a few smaller vesicles (small arrow). DPPC/egg PG/pal-
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FIGURE 6 (A) Epifluorescence image of binding of antibody (FITC-conjugated GAR antibody and PR anti-SP-B[l-25] antibody) to SP-B(l-25)
which had adsorbed to preformed DPPC/egg PG vesicles. Arrows mark fluorescence associated with tubular vesicles that were in a slightly different
focal plane than the DIC image (B), thus only the corresponding multilamellar vesicles were imaged.
mitic acid liposomes consisted mainly ofthe later popula-
tion and range in size from -4 to 100 ,um. SP-B(1-25)
added after vesicle formation did not effect the shape of
these mixtures. SP-B(1-25), SP-B(78), and SP-B(49-66)
when included in the lipid film also had no effect. The
shape and structure of the vesicles seemed to be domi-
768 Biophysical Journal
nated by the lipid behavior, and was relatively indepen-
dent of the presence or absence of protein or peptide.
It is likely that much of this shape transformation ef-
fect can be accounted for by the lipid phase behavior of
each lipid. DPPC is a zwitterionic lipid species; in the
absence of charged interactions, interbilayer distances
Volume 63 September 1992
possibly enhanced mixing. Due to interbilayer repulsion,
envapsulated vesicles could no longer pack closely to-
gether and unilamellar vesicles were often formed.
This is the first time to our knowledge that the morpho-
logical features of the three lipid component Tanaka
mixture have been compared with the binary mixtures.
These observations are necessary because air-water in-
terfacial adsorption measurements are often made using
vesicle solutions spread at the interface or injected into
the subphase (3, 7, 9, 15, 23, 27, 54). It has been shown
that the Tanaka mixture spreads more quickly than any
of the two component derivations and the addition of
lung surfactant protein enhances surface adsorption (9).
The tendency toward unilamellar vesicles may be an in-
tegral part of rapid spreading.
FIGURE 7 Weak and diffuse binding of antibody (FITC-conjugated
GAR antibody and PR anti-SP-B[49-66] antibody) to reduced SP-B(l -
78) associated with vesicles formed of Tanaka lipids. Arrows mark a
corresponding vesicle in epifluorescence mode (A) and DIC (B). Note
that the vesicles have a flattened appearance apparently due to the
presence of the reducing agent (5 mM dithiothreitol).
are mainly limited by the short ranged repulsive hydra-
tion force (41, 44-46) and densely packed structures are
formed. DSC studies indicate that palmitic acid packs
well with DPPC and actually tends to raise the phase
transition temperature (47, 48). Therefore, DPPC/PA
vesicles were not hydrated above the gel-liquid crystal-
line phase transition temperature which begins at
-45°C for this mixture. This could have caused the for-
mation of small aggregates. Egg PG had the most dra-
matic effect on the appearance of the vesicles. The hy-
drocarbon chain length and degree of unsaturation is
inhomogeneous in egg PG. This type of inhomogeneity
has a fluidizing effect on the lipid mixture, thus lowering
the main phase transition temperature (41), so that the
structures contained no sharp edges at room tempera-
ture. Additionally, because of the presence of negatively
charged PG head groups, interbilayer distances are lim-
ited by longer ranged repulsive electrostatic interactions
(49-5 1), resulting in less densely packed structures (42).
It is possible that the egg PG preferentially partitioned
into the mainly unilamellar vesicles. Addition of pal-
mitic acid, which is greater than 99% negatively charged
at pH 7.2 (pKa of -5.0 [52, 53]), increased charge and
CONCLUSIONS
The amphipathic lung surfactant peptide, SP-B(1-25),
localizes at the lipid bilayer surface ofsynthetic lung sur-
factant vesicles and is surface accessible to antibodies
targeted against it. In addition, SP-B(1-25) (contains
four positively charged amino acid residues) readily ad-
sorbs to negatively charged lipid bilayers but is disin-
clined to adsorb to neutral vesicles. It appears that ad-
sorption into a lipid bilayer involves an electrostatic at-
traction because adsorption to uncharged layers is weak.
For antibody binding to occur, it is probable that the
positively charged residues of SP-B(1-25) amphipathic
alpha helix are exposed to the hydrophilic environment
of the lipid headgroups and the hydrophobic residues
interact with the lipid fatty acid chains. The location of
SP-B( 1-25) relative to the lipid bilayer, as well as its inter-
action with a negatively charged bilayer, may be an inte-
gral part of the enhanced effectiveness of synthetic lung
surfactant containing SP-B( 1-25) and negatively charged
lipids. SP-B(49-66), when incorporated into giant vesi-
cles, is not accessible to antibodies targeted against it
from aqueous solution. Due to its lack of water solubil-
ity, and its high affinity for lipids and nonpolar solvents,
we are sure that SP-B(49-66) is located within the vesicle
bilayers, although it is not in contact with the lipid-water
interface. Even though SP-B(49-66) forms an alpha helix
in a lipid environment, its increased hydrophobicity
should cause it to locate much more deeply within the
hydrophobic interior of lipid bilayers than SP-B( 1-25).
Only the COOH-terminal region (49-66 residues) of
lipid associated monomeric SP-B(1-78) is accessible to
antibody. The weak fluorescence associated with the an-
tibody recognition suggests that SP-B( 1-78) assumes cer-
tain orientations in the bilayer such that the COOH-ter-
minus is accessible to the aqueous environment. In the
monomeric form, the COOH-terminus residues 61-71
have a high hydrophobic moment (23). This additional
amphipathicity may allow the COOH-terminus to orient
near enough to the surface so that the 49-66 sequence of
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FIGURE 8 Liposome structures formed by mixtures of DPPC, DPPC/egg PG, DPPC/palmitic acid, DPPC/egg PO/palmitic acid hydrated in 10
mM PBS and 0.5% BSA. SP-B(l-25) added to the solution did not affect the appearance ofthe structures. Arrows mark typical structures. (A) DPPC
formed multilayer structures. (B) DPPC/palmitic acid formed smaller and less densely packed structures. (C) DPPC/egg PG liposomes consisted of
a bimodal population. The large arrow marks a typical example of large densely packed liposomes from one of the populations. The small arrow
indicates a typical example of vesicles that are unilamellar or loosely encapsulate a few smaller vesicles that constituted the second population. (D)
DPPC/egg PG/palmitic acid formed mainly unilamellar vesicles or vesicles containing a few entrapped vesicles.
the full synthetic protein is accessible to antibody, unlike
the 49-66 peptide. Alternately, as the full synthetic pro-
tein also contains the surface-associated 1-25 sequence,
770 Biophysical Journal
the 49-66 sequence may be located more closely to the
aqueous interface, allowing the weak binding we ob-
served.
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FIGURE 8 (continued)
We also observed that lipid associated monomeric and
oligomeric SP-B( 1-78) was not bound by the antibody to
the 1-25 peptide. Preliminary immunostaining results
also have shown that the 1-25 region ofSP-B( 1-78) is not
bound by antibody to SP-B(1-25) peptide, most likely
due to some conformation difference between the pep-
tide and the full synthetic protein, and not to the surface
Longo et at. Lipid Association of Protein SP-B
accessibility of the protein in the bilayer. As a result of
the amphipathic nature of the 1-25 region, we expect
that this sequence is located in the bilayer in a similar
fashion to the 1-25 peptide. However, the central region
ofSP-B(1-78) contains a high percentage ofhydrophobic
residues and may be interacting more strongly with the
hydrophobic lipid core than the NH2-terminus or
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COOH-terminus. In future work, we plan a comparison
ofthe binding characteristics ofthe synthetic SP-B( 1-78)
and native SP-B protein in lipid bilayers which should
indicate differences in their conformation and topogra-
phy in the lipid bilayer.
An advantage of this flow immunofluorescence tech-
nique is that the topography ofpeptide and protein mole-
cules can be assessed in a realistic and flexible model
membrane system ofgiant liposomes. In this system, it is
convenient to change the composition of the lipid sys-
tem, add components to solution (such as reductants
and ions), and control the temperature of the system,
while following the results visually. The binding ofwater
soluble proteins to the lipid bilayer or antibody binding
to lipid associated peptides or protein segments can be
monitored according to changes made in the system in a
simple and straightforward manner.
We have also been able to assess general morphologi-
cal differences of vesicles formed from single compo-
nents and binary mixtures of the Tanaka model surfac-
tant. Only the three component Tanaka lipid mixture
forms a population of mainly spherical unilamellar vesi-
cles. The tendency to form unilamellar vesicles is cer-
tainly related to more rapid spreading of this mixture at
an air-water interface compared with two component
derivations ofthe Tanaka mixture that form multilamel-
lar particles. The full synthetic protein or any ofthe pep-
tide segments of SP-B do not appear to influence the
number of vesicle layers or their configuration, so SP-B
protein is likely to provide an additional mechanism (re-
lated to surface association of the 1-25 region with Ta-
naka lipid vesicles) to enhance adsorption to the air-
water interface, as well as lowering surface tension.
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